Literature DB >> 6838187

Single-dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients.

U B Schaad, P A Casey, D L Cooper.   

Abstract

Pharmacokinetics of a parenteral formulation comprised of 5 parts of amoxicillin and 1 part of clavulanic acid were determined in 12 pediatric patients, 2 to 14 years of age. A single dose amounting to 25 mg of amoxicillin and 5 mg of clavulanic acid per kg of body weight was infused intravenously over 2 min. Mean plasma concentrations 5 min after dosing were 89.4 micrograms of amoxicillin per ml and 19.5 micrograms of clavulanic acid per ml. Terminal phase plasma half-lives were 1.2 and 0.8 h, respectively. The data acquired in this study indicate that amoxicillin and clavulanic acid are pharmacokinetically compatible. Moreover, taken with assessment of microbiological activities by others, the present data suggest that intravenous administration of 25 mg of amoxicillin plus 5 mg of clavulanic acid per kg every 6 h is a reasonable starting regimen for assessing the activity of the combined drug formulation in noninvasive childhood diseases caused by Haemophilus influenzae, Staphylococcus aureus, Streptococci spp., Neisseria spp., Branhamella catarrhalis, and other susceptible organisms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6838187      PMCID: PMC186032          DOI: 10.1128/AAC.23.2.252

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study.

Authors:  A P Ball; A M Geddes; P G Davey; I D Farrell; G R Brookes
Journal:  Lancet       Date:  1980-03-22       Impact factor: 79.321

2.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

3.  Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid.

Authors:  G Ninane; J Joly; M Kraytman; P Piot
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

4.  In vitro-activity of clavulanic acid and amoxicillin combined against amoxicillin-resistant bacteria.

Authors:  G Peters; G Pulverer; M Neugebauer
Journal:  Infection       Date:  1980       Impact factor: 3.553

5.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

6.  In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b.

Authors:  R Yogev; C Melick; W J Kabat
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

7.  Pharmacokinetics of intravenous amoxicillin in pediatric patients.

Authors:  R C Rudoy; N Goto; D Pettit; H Uemura
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

8.  Clinicopharmacological evaluation of amoxicillin and probenecid against bacterial meningitis.

Authors:  J C Craft; W E Feldman; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

9.  A combination of amoxicillin and clavulanic acid in the treatment of respiratory tract infections caused by amoxicillin-resistant haemophilus influenzae.

Authors:  H Beeuwkes; V H Rutgers
Journal:  Infection       Date:  1981       Impact factor: 3.553

10.  Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus.

Authors:  R G Washburn; D T Durack
Journal:  J Infect Dis       Date:  1981-09       Impact factor: 5.226

View more
  9 in total

Review 1.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation.

Authors:  Hui-Han Chen; Andrew Stringer; Tadesse Eguale; Gauri G Rao; Sachiko Ozawa
Journal:  Am J Trop Med Hyg       Date:  2019-11       Impact factor: 2.345

Review 3.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

4.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

Review 5.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

6.  Did the accuracy of oral amoxicillin dosing of children improve after British National Formulary dose revisions in 2014? National cross-sectional survey in England.

Authors:  Olivia Rann; Mike Sharland; Paul Long; Ian C K Wong; Anthony A Laverty; Alex Bottle; Charlotte I Barker; Julia Bielicki; Sonia Saxena
Journal:  BMJ Open       Date:  2017-09-27       Impact factor: 2.692

7.  Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin.

Authors:  F F Horber; F J Frey; C Descoeudres; A T Murray; F C Reubi
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

8.  Bactericidal interactions of a beta-lactam and beta-lactamase inhibitors in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive overproducer of type Id beta-lactamase.

Authors:  A S Bayer; M Selecky; K Babel; L Hirano; J Yih; T R Parr
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

9.  Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review.

Authors:  Fleur M Keij; Gerdien A Tramper-Stranders; Birgit C P Koch; Irwin K M Reiss; Anouk E Muller; René F Kornelisse; Karel Allegaert
Journal:  Clin Pharmacokinet       Date:  2022-03-31       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.